Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Vet Parasitol ; 197(1-2): 95-103, 2013 Oct 18.
Artículo en Inglés | MEDLINE | ID: mdl-23680543

RESUMEN

Bovine besnoitiosis caused by Besnoitia besnoiti is a chronic and debilitating disease. The most characteristic clinical signs of chronic besnoitiosis are visible tissue cysts in the scleral conjunctiva and the vagina, thickened skin and a generally poor body condition. However, many seropositive animals remain subclinically infected, and the role that these animals may play in spreading the disease is not known. The aim of the present study was to assess the intra-organ parasite distribution, the parasite load and the parasite-associated lesions in seropositive but subclinically infected animals. These animals were seropositive at the time of several consecutive samplings, had visible tissue cysts in the past and, at time of slaughter, had detectable specific anti-Besnoitia spp. antibody levels, but they did not show evident clinical signs at culling. Thus, histopathological, immunohistochemical and molecular analyses of several samples from the respiratory tract, reproductive tract, other internal organs and skin from six cows were performed. The tissue cysts were located primarily in the upper respiratory tract, i.e., in the rhinarium and larynx/pharynx (four cows), followed by the distal genital tract (vulva/vagina) and the skin of the neck (three and two cows, respectively, out of the four cows with cysts in the respiratory tract). We were unable to detect any parasites in the two remaining cows. Cysts were associated with a significant non-purulent inflammatory infiltrate consisting predominantly of T lymphocytes and activated monocytes/macrophages in two cows. The parasite burden, estimated by quantitative real-time PCR, was very low. It is noteworthy that the only animal that showed a recent increase in the antibody titre had the highest parasite burden and the most conspicuous inflammatory reaction against the cysts. In conclusion, although these cows no longer displayed any visible signs of besnoitiosis, they remained infected. Therefore, cows without visible signs of disease may still be able to transmit the parasite.


Asunto(s)
Enfermedades de los Bovinos/parasitología , Coccidiosis/veterinaria , Animales , Bovinos , Enfermedades de los Bovinos/patología , Enfermedad Crónica , Coccidiosis/parasitología , Coccidiosis/patología , Femenino
2.
Vet Rec ; 166(26): 818-22, 2010 Jun 26.
Artículo en Inglés | MEDLINE | ID: mdl-20581359

RESUMEN

An indirect ELISA based on a soluble extract of Besnoitia besnoiti tachyzoites was developed and standardised. A set of positive and negative reference bovine sera were characterised using an immunofluorescence antibody test and Western blot. A cut-off with a relative index per cent of 8.1 was determined for equal sensitivity and specificity (100 per cent) by two-graph receiver operating characteristic analysis. Cross-reactions with other closely related Apicomplexan parasites were discarded. The standardised ELISA was then used during an outbreak of bovine besnoitiosis in a mountainous area of central Spain. The outbreak occurred in nine herds, and 358 animals that shared grazing lands during the summer season were affected. Clinical examination and blood sampling were carried out for all animals, and skin biopsies were obtained from animals with skin lesions. The confirmatory diagnosis was carried out by means of the indirect ELISA, together with the identification of tissue cysts by microscopy. Most of the animals were seropositive (90.5 per cent), but only 43 per cent of seropositive cattle developed clinical signs compatible with besnoitiosis. Additionally, a significant increase in seroprevalence and clinical signs was found to be associated with the increasing age of the animals, suggesting rapid horizontal transmission of the disease.


Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Enfermedades de los Bovinos/epidemiología , Coccidiosis/veterinaria , Brotes de Enfermedades/veterinaria , Ensayo de Inmunoadsorción Enzimática/veterinaria , Sarcocystidae/inmunología , Animales , Bovinos , Enfermedades de los Bovinos/diagnóstico , Enfermedades de los Bovinos/transmisión , Coccidiosis/diagnóstico , Coccidiosis/epidemiología , Coccidiosis/transmisión , Reacciones Cruzadas , Femenino , Masculino , Curva ROC , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Estudios Seroepidemiológicos , España/epidemiología
3.
Vaccine ; 27(48): 6695-703, 2009 Nov 12.
Artículo en Inglés | MEDLINE | ID: mdl-19747996

RESUMEN

Canine visceral leishmaniasis is a serious public health concern in the Mediterranean basin since dogs are the main Leishmania infantum reservoir. However, there is not a vaccination method in veterinary use in this area, and therefore the development of a vaccine against this parasite is essential for the possible control of the disease. Previous reports have shown the efficacy of heterologous prime-boost vaccination with the pCIneo plasmid and the poxvirus VV (both Western Reserve and MVA strains) expressing L. infantum LACK antigen against canine leishmaniasis. As pCIneo-LACK plasmid contains antibiotic resistance genes, its use as a profilactic method is not recommended. Hence, the antibiotic resistance gene free pORT-LACK plasmid is a more suitable tool for its use as a vaccine. Here we report the protective and immunostimulatory effect of the prime-boost pORT-LACK/MVA-LACK vaccination tested in a canine experimental model. Vaccination induced a reduction in clinical signs and in parasite burden in the liver, an induction of the Leishmania-specific T cell activation, as well as an increase of the expression of Th1 type cytokines in PBMC and target organs.


Asunto(s)
Antígenos de Protozoos/inmunología , Enfermedades de los Perros/inmunología , Vacunas contra la Leishmaniasis/inmunología , Leishmaniasis Visceral/veterinaria , Proteínas Protozoarias/inmunología , Células TH1/inmunología , Animales , Anticuerpos Antiprotozoarios/sangre , Citocinas/inmunología , ADN Protozoario/inmunología , Enfermedades de los Perros/prevención & control , Perros , Femenino , Inmunización Secundaria , Inmunoglobulina G/sangre , Leishmania infantum/inmunología , Leishmaniasis Visceral/inmunología , Leishmaniasis Visceral/prevención & control , Hígado/parasitología , Activación de Linfocitos , Masculino , Plásmidos , Vacunas de ADN/inmunología
4.
Vaccine ; 26(3): 333-44, 2008 Jan 17.
Artículo en Inglés | MEDLINE | ID: mdl-18093705

RESUMEN

Leishmaniasis caused by Leishmania infantum is a severe endemic disease in the Mediterranean basin, being domestic dogs the main reservoir of the disease that plays a key role in the transmission to humans. Studies on vaccines against canine leishmaniasis, aimed to modify the T cell repertoire, have advanced in recent years. LACK vaccination assays, using protein or DNA vectors, show protection against cutaneous L. major infections by redirecting the early IL-4 responses to a protective Th1 response. The aim of this study was to define the effectiveness and type of immune response in a canine visceral leishmaniasis model of two poxvirus vectors (Western reserve strain, WR and modified vaccinia virus Ankara, MVA) expressing the LACK protein of L. infantum in prime/boost vaccination protocols. The results obtained showed that dog vaccination priming with DNA-LACK followed by a booster with MVA-LACK or rVV-LACK triggered a Th1 type of immune response, leading to protection against canine visceral leishmaniasis. This protection correlated with absence of visceral leishmaniasis symptoms, lower Leishmania-specific antibodies, higher degree of T cell activation in Leishmania-target organs and higher synthesis of Th1 cytokines. In addition, we found that dogs boosted with the non-replicative virus show less VL symptoms and higher degree of T cell activation, providing evidences for a clear advantage of MVA-LACK as a vaccination vector against canine visceral leishmaniasis.


Asunto(s)
Antígenos de Protozoos/inmunología , Enfermedades de los Perros/prevención & control , Vectores Genéticos , Leishmaniasis Visceral/veterinaria , Proteínas Protozoarias/inmunología , Células TH1/inmunología , Vacunas de ADN , Virus Vaccinia/genética , Animales , Antígenos de Protozoos/genética , Antígenos de Protozoos/metabolismo , Enfermedades de los Perros/inmunología , Enfermedades de los Perros/parasitología , Perros , Inmunización/veterinaria , Inmunización Secundaria/veterinaria , Leishmania infantum/inmunología , Leishmaniasis Visceral/inmunología , Leishmaniasis Visceral/parasitología , Leishmaniasis Visceral/prevención & control , Proteínas Protozoarias/genética , Proteínas Protozoarias/metabolismo , Vacunas Antiprotozoos/administración & dosificación , Vacunas Antiprotozoos/genética , Vacunas Antiprotozoos/inmunología , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/metabolismo , Vacunas de ADN/administración & dosificación , Vacunas de ADN/genética , Vacunas de ADN/inmunología , Virus Vaccinia/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA